Amneal completes $2.7B refinancing: $2.1B term loan and $600M notes

Amneal Pharmaceuticals, Inc.

Borrowed $2.1B of new seven-year term B loans due Aug 2032; margin SOFR+3.50% or base+2.50%.
Issued $600M 6.875% senior secured notes due Aug 2032; proceeds used to refinance existing debt.
Amended ABL facility extends maturity to Aug 2030; $600M revolving commitments unchanged.
Refinanced existing $2.26B term loans in full and repaid all ABL borrowings with net proceeds.

item 1.01item 2.03item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.